Mechanisms of resistance to RAF inhibitors in melanoma

The recent RAF inhibitor trial with PLX4032/RG7204 in late-stage mutant B-RAF melanoma patients has been lauded as a success story for personalized cancer therapy since short-term clinical responses were observed in the majority patients. However, initial responses were followed by subsequent tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Aplin, Andrew E., Kaplan, Fred M., Shao, Yongping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3156870/
https://www.ncbi.nlm.nih.gov/pubmed/21593776
http://dx.doi.org/10.1038/jid.2011.147
Descripción
Sumario:The recent RAF inhibitor trial with PLX4032/RG7204 in late-stage mutant B-RAF melanoma patients has been lauded as a success story for personalized cancer therapy since short-term clinical responses were observed in the majority patients. However, initial responses were followed by subsequent tumor re-growth and a subset of patients showed intrinsic resistance. Bi-directional translational efforts are now essential to determine the mechanisms underlying acquired/secondary and intrinsic resistance to RAF inhibitors.

Ejemplares similares